Fetal proteins and chronic treatment with low-dose erythropoietin

Journal of Laboratory and Clinical Medicine

Volumn 129, Issue 2, 1997, Pages 193-199

  Bellizzi, Vincenzo ^a   De Nicola, Luca ^b   Ames, Paolo ^b   Libertino, Rosanna ^b   Terracciano, Vincenzo ^b   Cianciaruso, Bruno ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031080518     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(97)90139-6     Document Type: Article

References (38)

1. Stockenhuber F, Kurz RW, Geissler K, Jahn C, Hinterberger W, Balcke P, et al. Recombinant human erythropoietin activates a broad spectrum of progenitors cells. Kidney Int 1990; 37:150-6.
2. Horina JH, Schmid CR, Roob JM, Winkler HM, Samitz MA, Hammer HF, et al. Bone marrow changes following treatment of renal anemia with erythropoietin. Kidney Int 1991; 40:917-22.
3. Jaar B, Baillou C, Viron B, Michel C, Mignon F, Najman A. Long-term effects of recombinant human erythropoietin on bone marrow progenitor cells. Nephrol Dial Transplant 1993; 8:614-20.
4. Anagnostou A, Sun Lee E, Kessimian N, Levinson R, Steiner M. Erythropoietin has mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87: 5978-82.
5. Al-Khatti AA, Veith RW, Papayannopoulou T, Fritsch EF, Goldwasser E, Stamatoyannopoulos G. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med 1987;317:415-20.
6. Stamatoyannopoulos G, Veith R, Al-Khatti AA, Papayannopoulou T. Induction of fetal hemoglobin by cell cycle-specific drugs and recombinant erythropoietin. Am J Pediatr Hematol Oncol 1990;12:21-6.
7. Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA 1979;76:670-2.
8. Ley TJ, De Simone J, Anagnou NP, Keller GH, Humphries RK, Turner P, et al. 5-Azacytidine selectively increases γ-globin synthesis in a patient with β+-thalassemia. N Engl J Med 1982;307:1469-75.
9. Results of a phase III multicenter clinical trial. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989;111:992-1000.
10. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 1990;300:573-8.
11. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987;316: 73-8.
12. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321: 158-62.
13. McGonigle RJS, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 1984;25:437-44.
14. Witt I, Muller H. Phosphorus and hexose content of human fetal fibrinogen. Biochem Biophys Acta 1970;221:402-6.
15. Di Minno G, Mancini M. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 1990;10:1-7.
16. Sherwin RS, Tamborlane WV. Metabolic control and diabetic complications. In: Diabetes mellitus, management and complications. New York: Churcill Livingstone, 1995:1-29.
17. Martinez J, Barsigian C. Biology of disease. Carbohydrate abnormalities of N-linked plasma glycoproteins in liver disease. Lab Invest 1987;57:240-57.
18. Betke K, Marti HR, Schlichet I. Estimation of small percentages of foetal haemoglobin. Nature 1959;184:1877-9.
19. Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem 1959;234:1971.
20. Sundal E, Kaeser U. Correction of anemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 hemodialysis-dependent patients. Nephrol Dial Transplant 1989;4:979-87.
21. Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987;295:1017-20.
22. Papayannopoulou T, Brice M, Stamatoyannopoulos G. Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells. Proc Natl Acad Sci USA 1977;74:2923-7.
23. Stamatoyannopoulos G, Veith R, Galanello R, Papayannopoulou T. Hb F production in stressed erythropoiesis: observation and kinetic models. Ann NY Acad Sci 1985:445:188-97.
24. Torrealba de Ron AT, Papayannopoulou T, Knapp MS, Fu MF, Knitter G, Stamatoyannopoulos G. Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5-Azacytidine. Blood 1984;63:201-10.
25. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. New Engl J Med 1988;318:96-9.
26. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AN. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 1990; 322:1037-45.
27. Charache S, Dover GJ, Moore RD. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:255-65.
28. Beliles RP, Makris NG, Scott WJ. Consideration of pharmacokinetics and temporal sensitivity for hydroxyurea in relation to teratogenic potential. J Am Coll Toxicol 1991;10:269-78.
29. Al-Khatti A, Umemura T, Clow J, Abels RI, Vance J, Papayannopoulou T, et al. Erythropoietin stimulates F-reticulocyte formation in sickle cell anemia. Trans Assoc Am Phys 1988;101:54-61.
30. Nagel RL, Vichinsky E, Shah M, Johnson R, Spadacino E, Fabry ME, et al. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a doubleblind study. Blood 1993;81:9-14.
31. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 1993;238:73-80.
32. Rachmilewitz E, Goldfarb A, Dover G. Administration of erythropoietin to patients with β-thalassemia intermedia. A preliminary trial. Blood 1991;78:1145-51.
33. Olivieri NF, Freedman MH, Perrine SP, Dover G, Sheridan B, Essentain DL, et al. Trial of recombinant human erythropietin: three patients with thalassemia intermedia. Blood 1992;80:3258-60.
34. Bourantas KL, Georgiou I, Seferiadis K. Fetal globin stimulation during a short-term trial of erythropoietin in HbS/ Beta-thalassemia patients. Acta Haematol 1994;92:79-82.
35. Kaushansky K, Broudy VC, Grossmann A, Humes J, Lin N, Ren HP, et al. Thrombopoietin expands erythroid progenitors, increases red cell production and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995; 96:1683-7.
36. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-48.
37. Sherwood JB, Goldwasser E, Chilcote R, Carmichael LD, Nagel RD. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 1986;67:46-9.
38. Manor D, Fibach E, Goldfarb A, Rachmilewitz EA. Erythropoietin activity in the serum of beta thalassemic patients. Scand J Hematol 1986;37:221.